Compugen secures licensing deal with Gilead for IL-18 antibody cancer program, with $60M upfront

Compugen is set to receive an upfront payment of $60 million from Gilead to kickstart an exclusive licensing deal for the biotech’s anti-interleukin-18 protein binding antibody program for solid tumors, including the preclinical candidate COM503.

According to the companies, the licensing deal is worth $848 million, with Compugen set to…
Click here to view original post